Anbio Biotechnology NNNN

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $8.65M, +5.6% YoY · Filed Apr 7, 2026

Anbio Biotechnology (NNNN) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $8.6 million and net income of $6.4 million.

Revenue
$8.65M
+5.6% vs prior year
Net income
$6.40M
+169.9% vs prior year
Operating cash flow
$-6.74M
-423.9% vs prior year
Free cash flow
—
EPS
$0.15
+162.5% vs prior year
Dividend per share
None
Shares outstanding
—
Net cash
—
Operating margin
66.7%
FY 2025

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
NNNN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Frankfurt Am Main, Germany
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1982708

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Revenue
$8.6M
$8.2M
Operating income
$5.8M
$2.0M
Net income
$6.4M
$2.4M
Diluted EPS
$0.15
$0.06
Operating cash flow
-$6.7M
$2.1M
Total assets
$30.2M
$18.9M
Total liabilities
$87,836
$1.7M
Stockholders' equity
$30.2M
$17.2M
Cash and investments
$11.9M
$11.8M

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) May 19, 2026 May 19, 2026
6-K Current report (foreign issuer) Apr 27, 2026 Apr 27, 2026
20-F/A Amended annual report (foreign issuer) Apr 9, 2026 Dec 31, 2025
20-F Annual report (foreign issuer) Apr 7, 2026 Dec 31, 2025
6-K Current report (foreign issuer) Feb 17, 2026 Feb 17, 2026
6-K Current report (foreign issuer) Jan 26, 2026 Jan 26, 2026

All 43 Anbio Biotechnology SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.